Idarucizumab for Dabigatran reversal: full cohort analysis
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2017
|
| In: |
The New England journal of medicine
Year: 2017, Jahrgang: 377, Heft: 5, Pages: 431-441 |
| ISSN: | 1533-4406 |
| Online-Zugang: | Verlag, Volltext: https://www.nejm.org/doi/10.1056/NEJMoa1707278
|
| Verfasserangaben: | Charles V. Pollack, Jr., M.D., Paul A. Reilly, Ph.D., Joanne van Ryn, Ph.D., John W. Eikelboom, M.B., B.S., Stephan Glund, Ph.D., Richard A. Bernstein, M.D., Ph.D., Robert Dubiel, Pharm.D., Menno V. Huisman, M.D., Ph.D., Elaine M. Hylek, M.D., Chak‑Wah Kam, M.D., Pieter W. Kamphuisen, M.D., Ph.D., Jörg Kreuzer, M.D., Jerrold H. Levy, M.D., Gordon Royle, M.D., Frank W. Sellke, M.D., Joachim Stangier, Ph.D., Thorsten Steiner, M.D., Peter Verhamme, M.D., Bushi Wang, Ph.D., Laura Young, M.D., and Jeffrey I. Weitz, M.D. |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1576386961 | ||
| 003 | DE-627 | ||
| 005 | 20220814163930.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180614s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMoa1707278 |2 doi | |
| 035 | |a (DE-627)1576386961 | ||
| 035 | |a (DE-576)506386961 | ||
| 035 | |a (DE-599)BSZ506386961 | ||
| 035 | |a (OCoLC)1341011597 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Pollack, Charles V. |e VerfasserIn |0 (DE-588)140620974 |0 (DE-627)703735160 |0 (DE-576)319144860 |4 aut | |
| 245 | 1 | 0 | |a Idarucizumab for Dabigatran reversal |b full cohort analysis |c Charles V. Pollack, Jr., M.D., Paul A. Reilly, Ph.D., Joanne van Ryn, Ph.D., John W. Eikelboom, M.B., B.S., Stephan Glund, Ph.D., Richard A. Bernstein, M.D., Ph.D., Robert Dubiel, Pharm.D., Menno V. Huisman, M.D., Ph.D., Elaine M. Hylek, M.D., Chak‑Wah Kam, M.D., Pieter W. Kamphuisen, M.D., Ph.D., Jörg Kreuzer, M.D., Jerrold H. Levy, M.D., Gordon Royle, M.D., Frank W. Sellke, M.D., Joachim Stangier, Ph.D., Thorsten Steiner, M.D., Peter Verhamme, M.D., Bushi Wang, Ph.D., Laura Young, M.D., and Jeffrey I. Weitz, M.D. |
| 264 | 1 | |c 2017 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published on July 11, 2017 | ||
| 500 | |a Gesehen am 14.06.2018 | ||
| 700 | 1 | |a Steiner, Thorsten |d 1961- |e VerfasserIn |0 (DE-588)118107623 |0 (DE-627)079247407 |0 (DE-576)291718779 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d Waltham, Mass. : MMS, 1928 |g 377(2017), 5, Seite 431-441 |h Online-Ressource |w (DE-627)266889484 |w (DE-600)1468837-2 |w (DE-576)075962454 |x 1533-4406 |7 nnas |a Idarucizumab for Dabigatran reversal full cohort analysis |
| 773 | 1 | 8 | |g volume:377 |g year:2017 |g number:5 |g pages:431-441 |g extent:11 |a Idarucizumab for Dabigatran reversal full cohort analysis |
| 856 | 4 | 0 | |u https://www.nejm.org/doi/10.1056/NEJMoa1707278 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180614 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 118107623 |a Steiner, Thorsten |m 118107623:Steiner, Thorsten |d 910000 |d 911100 |e 910000PS118107623 |e 911100PS118107623 |k 0/910000/ |k 1/910000/911100/ |p 17 | ||
| 999 | |a KXP-PPN1576386961 |e 3012710639 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Charles V. Pollack, Jr., M.D., Paul A. Reilly, Ph.D., Joanne van Ryn, Ph.D., John W. Eikelboom, M.B., B.S., Stephan Glund, Ph.D., Richard A. Bernstein, M.D., Ph.D., Robert Dubiel, Pharm.D., Menno V. Huisman, M.D., Ph.D., Elaine M. Hylek, M.D., Chak‑Wah Kam, M.D., Pieter W. Kamphuisen, M.D., Ph.D., Jörg Kreuzer, M.D., Jerrold H. Levy, M.D., Gordon Royle, M.D., Frank W. Sellke, M.D., Joachim Stangier, Ph.D., Thorsten Steiner, M.D., Peter Verhamme, M.D., Bushi Wang, Ph.D., Laura Young, M.D., and Jeffrey I. Weitz, M.D."]},"id":{"eki":["1576386961"],"doi":["10.1056/NEJMoa1707278"]},"origin":[{"dateIssuedDisp":"2017","dateIssuedKey":"2017"}],"relHost":[{"origin":[{"publisher":"MMS ; MMS","dateIssuedKey":"1928","dateIssuedDisp":"1928-","publisherPlace":"Waltham, Mass. ; Boston, Mass."}],"id":{"eki":["266889484"],"zdb":["1468837-2"],"issn":["1533-4406"]},"name":{"displayForm":["Massachusetts Medical Society"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"New England journal of medicine","subtitle":"NEJM","title":"The New England journal of medicine"}],"pubHistory":["198.1928 -"],"part":{"year":"2017","issue":"5","pages":"431-441","text":"377(2017), 5, Seite 431-441","volume":"377","extent":"11"},"titleAlt":[{"title":"NEJM"}],"disp":"Idarucizumab for Dabigatran reversal full cohort analysisThe New England journal of medicine","note":["Gesehen am 04.08.25"],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"corporate":[{"roleDisplay":"Herausgebendes Organ","display":"Massachusetts Medical Society","role":"isb"}],"recId":"266889484"}],"physDesc":[{"extent":"11 S."}],"person":[{"display":"Pollack, Charles V.","roleDisplay":"VerfasserIn","role":"aut","family":"Pollack","given":"Charles V."},{"roleDisplay":"VerfasserIn","display":"Steiner, Thorsten","role":"aut","family":"Steiner","given":"Thorsten"}],"title":[{"title_sort":"Idarucizumab for Dabigatran reversal","subtitle":"full cohort analysis","title":"Idarucizumab for Dabigatran reversal"}],"language":["eng"],"recId":"1576386961","note":["Published on July 11, 2017","Gesehen am 14.06.2018"],"type":{"media":"Online-Ressource","bibl":"article-journal"}} | ||
| SRT | |a POLLACKCHAIDARUCIZUM2017 | ||